Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunosuppressants, Immunostimulants, Interferons and Others), By Route of Administration (Oral, Injectable and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and E-Commerce), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Dec 2024
Report ID: 135902
Number of Pages: 289
Format:

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Market Snapshot
  - 1.3. Market Overview
  - 1.4. Segment Overview
  - 1.5. Regional Overview
  - 1.6. Competitive Landscape
  - 1.7. Taxonomy
- 2. Global Market Overview
  - 2.1. Global Market Insights and Industry Overview
  - 2.2. Market Dynamics
    
    2.2.1. Drivers
    
    2.2.2. Restraints
    
    2.2.3. Opportunities
    
    2.2.4. Key Multiple Sclerosis Therapeutics Market Trends
  - 2.3. Regulatory Framework
  - 2.4. Opportunity Map Analysis
  - 2.5. Opportunity Orbits
  - 2.6. PESTLE Analysis
  - 2.7. PORTER’S Five Force Analysis
  - 2.8. Drivers & Restraints Impact Analysis
  - 2.9. Value Chain Analysis
    
    2.9.1. List of Raw Materials Suppliers
    
    2.9.2. List of Multiple Sclerosis Therapeutics Manufacturers
    
    2.9.3. List of Dealer/Distributors
  - 2.10. Regional Market Share and BPS Analysis
  - 2.11. Impact of Macro-economic Factors/Geopolitical Factors
- 3. Global Multiple Sclerosis Therapeutics Market Analysis and Forecast, By Segment, 2019-2033
  - 3.1. Key Findings
  - 3.2. Global Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2019-2033
  - 3.3. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
    
    3.3.1. Immunosuppressants
    
    3.3.1.1. Insights
    
    3.3.1.2. Key Takeaways
    
    3.3.2. Immunostimulants
    
    3.3.2.1. Insights
    
    3.3.2.2. Key Takeaways
    
    3.3.3. Interferons
    
    3.3.3.1. Insights
    
    3.3.3.2. Key Takeaways
    
    3.3.4. Others
    
    3.3.4.1. Insights
    
    3.3.4.2. Key Takeaways
  - 3.4. Global Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2019-2033
  - 3.5. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
    
    3.5.1. Oral
    
    3.5.1.1. Insights
    
    3.5.1.2. Key Takeaways
    
    3.5.2. Injectable
    
    3.5.2.1. Insights
    
    3.5.2.2. Key Takeaways
    
    3.5.3. Others
    
    3.5.3.1. Insights
    
    3.5.3.2. Key Takeaways
  - 3.6. Global Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2019-2033
  - 3.7. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
    
    3.7.1. Hospital Pharmacies
    
    3.7.1.1. Insights
    
    3.7.1.2. Key Takeaways
    
    3.7.2. Retail Pharmacies
    
    3.7.2.1. Insights
    
    3.7.2.2. Key Takeaways
    
    3.7.3. E-Commerce
    
    3.7.3.1. Insights
    
    3.7.3.2. Key Takeaways
- 4. Global Multiple Sclerosis Therapeutics Market Analysis and Forecast, By Region, 2019-2033
  - 4.1. Key Findings
  - 4.2. Global Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2019-2033
    
    4.2.1. North America
    
    4.2.1.1. Regional Insights
    
    4.2.2. Europe
    
    4.2.2.1. Regional Insights
    
    4.2.3. Asia Pacific
    
    4.2.3.1. Regional Insights
    
    4.2.4. Latin America
    
    4.2.4.1. Regional Insights
    
    4.2.5. Middle East & Africa
    
    4.2.5.1. Regional Insights
  - 4.3. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Region
- 5. North America Multiple Sclerosis Therapeutics Market Analysis and Forecast, 2019-2033
  - 5.1. Key Findings
  - 5.2. North America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2019-2033
  - 5.3. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - 5.4. North America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2019-2033
  - 5.5. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - 5.6. North America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2019-2033
  - 5.7. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - 5.8. North America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2019-2033
  - 5.9. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
    
    5.9.1. The US
    
    5.9.2. Canada
- 6. Europe Multiple Sclerosis Therapeutics Market Analysis and Forecast, 2019-2033
  - 6.1. Key Findings
  - 6.2. Europe Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2019-2033
  - 6.3. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - 6.4. Europe Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2019-2033
  - 6.5. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - 6.6. Europe Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2019-2033
  - 6.7. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - 6.8. Europe Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2019-2033
  - 6.9. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
    
    6.9.1. Germany
    
    6.9.2. The UK
    
    6.9.3. France
    
    6.9.4. Spain
    
    6.9.5. Italy
    
    6.9.6. Russia
    
    6.9.7. Netherland
    
    6.9.8. Rest of Europe
- 7. Asia Pacific Multiple Sclerosis Therapeutics Market Analysis and Forecast, 2019-2033
  - 7.1. Key Findings
  - 7.2. Asia Pacific Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2019-2033
  - 7.3. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - 7.4. Asia Pacific Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2019-2033
  - 7.5. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - 7.6. Asia Pacific Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2019-2033
  - 7.7. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - 7.8. Asia Pacific Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2019-2033
  - 7.9. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
    
    7.9.1. China
    
    7.9.2. Japan
    
    7.9.3. South Korea
    
    7.9.4. India
    
    7.9.5. Australia
    
    7.9.6. New Zealand
    
    7.9.7. Singapore
    
    7.9.8. Thailand
    
    7.9.9. Vietnam
    
    7.9.10. Rest of Asia Pacific
- 8. Latin America Multiple Sclerosis Therapeutics Market Analysis and Forecast, 2019-2033
  - 8.1. Key Findings
  - 8.2. Latin America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2019-2033
  - 8.3. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - 8.4. Latin America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2019-2033
  - 8.5. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - 8.6. Latin America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2019-2033
  - 8.7. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - 8.8. Latin America Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2019-2033
  - 8.9. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
    
    8.9.1. Brazil
    
    8.9.2. Mexico
    
    8.9.3. Rest of Latin America
- 9. Middle East & Africa Multiple Sclerosis Therapeutics Market Analysis and Forecast, 2019-2033
  - 9.1. Key Findings
  - 9.2. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2019-2033
  - 9.3. Middle East & Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - 9.4. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2019-2033
  - 9.5. Middle East & Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - 9.6. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2019-2033
  - 9.7. Middle East & Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - 9.8. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2019-2033
  - 9.9. Middle East & Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
    
    9.9.1. South Africa
    
    9.9.2. Saudi Arabia
    
    9.9.3. UAE
    
    9.9.4. Rest of Middle East & Africa
- 10. Competitive Landscape & Company Profiles
  - 10.1. Market Competition Scenario Analysis, By Company
    
    10.1.1. Key Takeaways
  - 10.2. Overview of Major Market Players
  - 10.3. Competitor Landscape
  - 10.4. Strategic Mapping
  - 10.5. Company Life Cycle Analysis
  - 10.6. Company Market Share Analysis
  - 10.7. Company Profiles
    
    10.7.1. Acorda Therapeutics Inc.
    
    10.7.1.1. Company Details
    
    10.7.1.2. Business Overview
    
    10.7.1.3. Product Portfolio
    
    10.7.1.4. Financial Insights
    
    10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.1.6. SWOT Analysis
    
    10.7.1.7. Geographic Footprint
    
    10.7.2. Bayer AG
    
    10.7.2.1. Company Details
    
    10.7.2.2. Business Overview
    
    10.7.2.3. Product Portfolio
    
    10.7.2.4. Financial Insights
    
    10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.2.6. SWOT Analysis
    
    10.7.2.7. Geographic Footprint
    
    10.7.3. Biogen
    
    10.7.3.1. Company Details
    
    10.7.3.2. Business Overview
    
    10.7.3.3. Product Portfolio
    
    10.7.3.4. Financial Insights
    
    10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.3.6. SWOT Analysis
    
    10.7.3.7. Geographic Footprint
    
    10.7.4. Bristol-Myers Squibb Company
    
    10.7.4.1. Company Details
    
    10.7.4.2. Business Overview
    
    10.7.4.3. Product Portfolio
    
    10.7.4.4. Financial Insights
    
    10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.4.6. SWOT Analysis
    
    10.7.4.7. Geographic Footprint
    
    10.7.5. F. Hoffmann-La Roche Ltd
    
    10.7.5.1. Company Details
    
    10.7.5.2. Business Overview
    
    10.7.5.3. Product Portfolio
    
    10.7.5.4. Financial Insights
    
    10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.5.6. SWOT Analysis
    
    10.7.5.7. Geographic Footprint
    
    10.7.6. Horizon Therapeutics plc
    
    10.7.6.1. Company Details
    
    10.7.6.2. Business Overview
    
    10.7.6.3. Product Portfolio
    
    10.7.6.4. Financial Insights
    
    10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.6.6. SWOT Analysis
    
    10.7.6.7. Geographic Footprint
    
    10.7.7. Johnson & Johnson Services Inc. (Janssen Global Services LLC)
    
    10.7.7.1. Company Details
    
    10.7.7.2. Business Overview
    
    10.7.7.3. Product Portfolio
    
    10.7.7.4. Financial Insights
    
    10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.7.6. SWOT Analysis
    
    10.7.7.7. Geographic Footprint
    
    10.7.8. Merck & Co., Inc.
    
    10.7.8.1. Company Details
    
    10.7.8.2. Business Overview
    
    10.7.8.3. Product Portfolio
    
    10.7.8.4. Financial Insights
    
    10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.8.6. SWOT Analysis
    
    10.7.8.7. Geographic Footprint
    
    10.7.9. Merck KGaA
    
    10.7.9.1. Company Details
    
    10.7.9.2. Business Overview
    
    10.7.9.3. Product Portfolio
    
    10.7.9.4. Financial Insights
    
    10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.9.6. SWOT Analysis
    
    10.7.9.7. Geographic Footprint
    
    10.7.10. Novartis AG
    
    10.7.10.1. Company Details
    
    10.7.10.2. Business Overview
    
    10.7.10.3. Product Portfolio
    
    10.7.10.4. Financial Insights
    
    10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.10.6. SWOT Analysis
    
    10.7.10.7. Geographic Footprint
    
    10.7.11. Pfizer Inc.
    
    10.7.11.1. Company Details
    
    10.7.11.2. Business Overview
    
    10.7.11.3. Product Portfolio
    
    10.7.11.4. Financial Insights
    
    10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.11.6. SWOT Analysis
    
    10.7.11.7. Geographic Footprint
    
    10.7.12. Sanofi SA
    
    10.7.12.1. Company Details
    
    10.7.12.2. Business Overview
    
    10.7.12.3. Product Portfolio
    
    10.7.12.4. Financial Insights
    
    10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.12.6. SWOT Analysis
    
    10.7.12.7. Geographic Footprint
    
    10.7.13. Takeda Pharmaceutical Company Limited.
    
    10.7.13.1. Company Details
    
    10.7.13.2. Business Overview
    
    10.7.13.3. Product Portfolio
    
    10.7.13.4. Financial Insights
    
    10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.13.6. SWOT Analysis
    
    10.7.13.7. Geographic Footprint
    
    10.7.14. Teva Pharmaceutical Industries Ltd.
    
    10.7.14.1. Company Details
    
    10.7.14.2. Business Overview
    
    10.7.14.3. Product Portfolio
    
    10.7.14.4. Financial Insights
    
    10.7.14.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.14.6. SWOT Analysis
    
    10.7.14.7. Geographic Footprint
    
    10.7.15. Viatris Inc. (Mylan NV)
    
    10.7.15.1. Company Details
    
    10.7.15.2. Business Overview
    
    10.7.15.3. Product Portfolio
    
    10.7.15.4. Financial Insights
    
    10.7.15.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.15.6. SWOT Analysis
    
    10.7.15.7. Geographic Footprint
- 11. Methodology and Data Source
  - 11.1. Methodology/Research Approach
  - 11.2. Market Size Estimation
  - 11.3. Market Breakdown and Data Triangulation
  - 11.4. Data Source
  - 11.5. Secondary Sources
  - 11.6. Primary Sources
  - 11.7. Appendix
  - 11.8. Disclaimer
- List of Tables
  - Table 1. Global Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 2. Global Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 3. Global Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 4. Global Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Region, 2019-2033
  - Table 5. North America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 6. North America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 7. North America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 8. North America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Country, 2019-2033
  - Table 9. The US Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 10. The US Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 11. The US Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 12. Canada Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 13. Canada Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 14. Canada Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 15. Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 16. Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 17. Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 18. Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Country, 2019-2033
  - Table 19. Germany Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 20. Germany Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 21. Germany Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 22. The UK Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 23. The UK Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 24. The UK Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 25. France Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 26. France Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 27. France Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 28. Spain Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 29. Spain Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 30. Spain Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 31. Italy Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 32. Italy Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 33. Italy Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 34. Russia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 35. Russia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 36. Russia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 37. Netherland Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 38. Netherland Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 39. Netherland Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 40. Rest of Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 41. Rest of Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 42. Rest of Europe Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 43. Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 44. Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 45. Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 46. Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Country, 2019-2033
  - Table 47. China Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 48. China Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 49. China Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 50. India Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 51. India Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 52. India Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 53. Japan Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 54. Japan Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 55. Japan Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 56. South Korea Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 57. South Korea Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 58. South Korea Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 59. Australia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 60. Australia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 61. Australia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 62. New Zealand Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 63. New Zealand Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 64. New Zealand Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 65. Singapore Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 66. Singapore Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 67. Singapore Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 68. Thailand Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 69. Thailand Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 70. Thailand Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 71. Vietnam Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 72. Vietnam Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 73. Vietnam Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 74. Rest of Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 75. Rest of Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 76. Rest of Asia Pacific Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 77. Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 78. Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 79. Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 80. Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Country, 2019-2033
  - Table 81. Brazil Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 82. Brazil Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 83. Brazil Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 84. Mexico Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 85. Mexico Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 86. Mexico Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 87. Rest of Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 88. Rest of Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 89. Rest of Latin America Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 90. Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 91. Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 92. Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 93. Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Country, 2019-2033
  - Table 94. South Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 95. South Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 96. South Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 97. Saudi Arabia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 98. Saudi Arabia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 99. Saudi Arabia Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 100. UAE Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 101. UAE Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 102. UAE Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
  - Table 103. Rest of Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Drug Class, 2019-2033
  - Table 104. Rest of Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Route of Administration, 2019-2033
  - Table 105. Rest of Middle East & Africa Multiple Sclerosis Therapeutics Market Value (US$ Mn), By Distribution Channel, 2019-2033
- List of Figures
  - Figure 1. Global Multiple Sclerosis Therapeutics Market Snapshot: Market Value (US$ Mn), 2019-2033
  - Figure 2. Opportunity Map
  - Figure 3. Opportunity Orbit
  - Figure 4. Regional Market Share and BPS Analysis in Multiple Sclerosis Therapeutics Market
  - Figure 5. Global Multiple Sclerosis Therapeutics Market Analysis, By Drug Class, 2019, 2023 and 2033
  - Figure 6. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - Figure 7. Global Multiple Sclerosis Therapeutics Market Analysis, By Route of Administration, 2019, 2023 and 2033
  - Figure 8. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - Figure 9. Global Multiple Sclerosis Therapeutics Market Analysis, By Distribution Channel, 2019, 2023 and 2033
  - Figure 10. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - Figure 11. Global Multiple Sclerosis Therapeutics Market Analysis, By Region, 2019, 2023 and 2033
  - Figure 12. Global Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Region
  - Figure 13. North America Multiple Sclerosis Therapeutics Market Analysis, By Drug Class, 2019, 2023 and 2033
  - Figure 14. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - Figure 15. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunosuppressants, 2019-2033
  - Figure 16. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunostimulants, 2019-2033
  - Figure 17. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Interferons, 2019-2033
  - Figure 18. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 19. North America Multiple Sclerosis Therapeutics Market Analysis, By Route of Administration, 2019, 2023 and 2033
  - Figure 20. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - Figure 21. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Oral, 2019-2033
  - Figure 22. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Injectable, 2019-2033
  - Figure 23. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 24. North America Multiple Sclerosis Therapeutics Market Analysis, By Distribution Channel, 2019, 2023 and 2033
  - Figure 25. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - Figure 26. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2019-2033
  - Figure 27. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by Retail Pharmacies, 2019-2033
  - Figure 28. North America Multiple Sclerosis Therapeutics Market (US$ Mn), by E-Commerce, 2019-2033
  - Figure 29. North America Multiple Sclerosis Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
  - Figure 30. North America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
  - Figure 31. Europe Multiple Sclerosis Therapeutics Market Analysis, By Drug Class, 2019, 2023 and 2033
  - Figure 32. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - Figure 33. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunosuppressants, 2019-2033
  - Figure 34. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunostimulants, 2019-2033
  - Figure 35. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Interferons, 2019-2033
  - Figure 36. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 37. Europe Multiple Sclerosis Therapeutics Market Analysis, By Route of Administration, 2019, 2023 and 2033
  - Figure 38. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - Figure 39. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Oral, 2019-2033
  - Figure 40. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Injectable, 2019-2033
  - Figure 41. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 42. Europe Multiple Sclerosis Therapeutics Market Analysis, By Distribution Channel, 2019, 2023 and 2033
  - Figure 43. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - Figure 44. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2019-2033
  - Figure 45. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by Retail Pharmacies, 2019-2033
  - Figure 46. Europe Multiple Sclerosis Therapeutics Market (US$ Mn), by E-Commerce, 2019-2033
  - Figure 47. Europe Multiple Sclerosis Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
  - Figure 48. Europe Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
  - Figure 49. Asia Pacific Multiple Sclerosis Therapeutics Market Analysis, By Drug Class, 2019, 2023 and 2033
  - Figure 50. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - Figure 51. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunosuppressants, 2019-2033
  - Figure 52. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunostimulants, 2019-2033
  - Figure 53. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Interferons, 2019-2033
  - Figure 54. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 55. Asia Pacific Multiple Sclerosis Therapeutics Market Analysis, By Route of Administration, 2019, 2023 and 2033
  - Figure 56. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - Figure 57. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Oral, 2019-2033
  - Figure 58. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Injectable, 2019-2033
  - Figure 59. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 60. Asia Pacific Multiple Sclerosis Therapeutics Market Analysis, By Distribution Channel, 2019, 2023 and 2033
  - Figure 61. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - Figure 62. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2019-2033
  - Figure 63. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by Retail Pharmacies, 2019-2033
  - Figure 64. Asia Pacific Multiple Sclerosis Therapeutics Market (US$ Mn), by E-Commerce, 2019-2033
  - Figure 65. Asia Pacific Multiple Sclerosis Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
  - Figure 66. Asia Pacific Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
  - Figure 67. Latin America Multiple Sclerosis Therapeutics Market Analysis, By Drug Class, 2019, 2023 and 2033
  - Figure 68. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - Figure 69. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunosuppressants, 2019-2033
  - Figure 70. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunostimulants, 2019-2033
  - Figure 71. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Interferons, 2019-2033
  - Figure 72. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 73. Latin America Multiple Sclerosis Therapeutics Market Analysis, By Route of Administration, 2019, 2023 and 2033
  - Figure 74. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - Figure 75. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Oral, 2019-2033
  - Figure 76. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Injectable, 2019-2033
  - Figure 77. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 78. Latin America Multiple Sclerosis Therapeutics Market Analysis, By Distribution Channel, 2019, 2023 and 2033
  - Figure 79. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - Figure 80. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2019-2033
  - Figure 81. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by Retail Pharmacies, 2019-2033
  - Figure 82. Latin America Multiple Sclerosis Therapeutics Market (US$ Mn), by E-Commerce, 2019-2033
  - Figure 83. Latin America Multiple Sclerosis Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
  - Figure 84. Latin America Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
  - Figure 85. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis, By Drug Class, 2019, 2023 and 2033
  - Figure 86. Middle East and Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Drug Class
  - Figure 87. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunosuppressants, 2019-2033
  - Figure 88. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Immunostimulants, 2019-2033
  - Figure 89. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Interferons, 2019-2033
  - Figure 90. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 91. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis, By Route of Administration, 2019, 2023 and 2033
  - Figure 92. Middle East and Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Route of Administration
  - Figure 93. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Oral, 2019-2033
  - Figure 94. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Injectable, 2019-2033
  - Figure 95. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Others, 2019-2033
  - Figure 96. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis, By Distribution Channel, 2019, 2023 and 2033
  - Figure 97. Middle East and Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Distribution Channel
  - Figure 98. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2019-2033
  - Figure 99. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by Retail Pharmacies, 2019-2033
  - Figure 100. Middle East and Africa Multiple Sclerosis Therapeutics Market (US$ Mn), by E-Commerce, 2019-2033
  - Figure 101. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis, By Country, 2019, 2023 and 2033
  - Figure 102. Middle East and Africa Multiple Sclerosis Therapeutics Market Attractiveness Analysis, By Country
- Acorda Therapeutics Inc.
- Bayer AG Company Profile
- Biogen
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Horizon Therapeutics plc
- Johnson & Johnson Services Inc. (Janssen Global Services LLC)
- Merck & Co., Inc.
- Merck KGaA Company Profile
- Novartis AG Company Profile
- Pfizer Inc Company Profile
- Sanofi SA
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceutical Industries Ltd. Company Profile
- Viatris Inc. (Mylan NV)
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 135902
Published Date Dec 2024
Rating
- ★★★★★
  
  ★★★★★
- (142)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)